The American Journal of Managed Care

LAMA-LABA Therapy Provides Improved Outcomes in COPD Over ICS-LABA

The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...
Medscape

LAMA and LABA in Patients with COPD Show Similar Risk of Cardiovascular Events

LAMAs were found to be safe and effective in the treatment of COPD and have been recommended by international clinical guidelines for the management of symptoms in COPD. A population-based cohort ...
Healio

Perioperative LAMA/LABA inhaled therapy optimal for patients with lung cancer, COPD

Please provide your email address to receive an email when new articles are posted on . Perioperative combination therapy using a long-acting muscarinic antagonist and long-acting beta agonist may be ...
Pulmonology Advisor

Extrafine BDP/FF/G May Improve Outcomes in Symptomatic COPD

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.
Healio

COPD exacerbation risk falls with dry powder vs. metered-dose, soft mist inhaler

New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD exacerbation with a dry powder inhaler vs. a metered-dose or soft mist ...
The American Journal of Managed Care

Leveraging GOLD Guidance and Value-Based Strategies in the Management of COPD

The GOLD 2023 and 2024 reports recommend that health professionals consider triple therapy (TT) entailing combined use of a long-acting β 2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), ...
The Cardiology Advisor

Umeclidinium-Vilanterol Tied to Better Outcomes Than Other LAMA-LABA Inhalers in Symptomatic COPD

Umeclidinium-vilanterol is associated with improved clinical outcomes in symptomatic patients with chronic obstructive pulmonary disease.
Medscape

LAMA/LABA Combos Tied to Varying Adverse Events in COPD

The risk for severe adverse events for patients with chronic obstructive pulmonary disease was significantly lower among those treated with glycopyrronium/indacaterol ...
MedPage Today

Triple Therapy for COPD: One Drug Too Many, Too Often?

SAN FRANCISCO -- Patients with chronic obstructive pulmonary disease (COPD) who changed treatment from so-called triple therapy to a two-drug product omitting the inhaled corticosteroid (ICS) ...
Morningstar

AeroRx Therapeutics Announces $21 Million Series A Financing to Advance Inhaled AERO-007, the First Nebulized LABA/LAMA for COPD, into Late-Stage Clinical Development

AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...
Monthly Prescribing Reference

Umeclidinium-Vilanterol Tied to Better Outcomes Than Other LAMA-LABA Inhalers in Symptomatic COPD

Researchers found that umeclidinium-vilanterol was associated with a lower risk for a first moderate or severe COPD exacerbation vs glycopyrrolate-formoterol. HealthDay News — Umeclidinium-vilanterol ...